First-of-its-Kind Randomized Clinical Trial Published in The Lancet Infectious Diseases Outlines Potential New Standard-Setting Best Practices for Peripheral IV Catheters

(2)
- There is robust evidence that the BD vascular care solution and skin antiseptic for peripheral intravenous catheters used in the CLEAN3 randomized clinical trial can help improve patient outcomes
- Compared with standard approaches, the BD vascular care solution reduced the relative risk of catheter failure by 27%, resulting in longer catheter dwell time without complications
- The use of 2% CHG 70% IPA single use, sterile applicator skin antiseptic reduced the risk of infectious complications (catheter colonization and local infection) by 92% compared with 5% povidone iodine (PVI) 69% ethanol
FRANKLIN LAKES, N.J., Feb. 2, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that new clinical data have found robust evidence that using a vascular care solution can help improve outcomes for patients requiring peripheral intravenous catheters (PIVCs).

Related Keywords

Poitiers ,Poitou Charentes ,France ,Netherlands ,Guenezan ,Bretagne ,Drugeon ,Franche Comter ,Kostenloser Wertpapierhandel ,Insyte Autoguard ,Olivier Mimoz ,Klaus Hoerauf ,Troy Kirkpatrick ,Kristenm Stewart ,Medication Delivery Solutions ,Poitiers University Hospital ,Appl Health Econ ,Lancet Infectious Diseases ,Professor Olivier Mimoz ,Becton Dickinson ,Infect Dis ,Infus Nurs ,Health Econ Policy ,பிரான்ஸ் ,நெதர்லாந்து ,ப்ரெடக்ந்ய் ,கிளாஸ் ொேறோஉப் ,டிராய் கர்க்‌ப்யாட்ரிக் ,மருந்து டெலிவரி தீர்வுகள் ,அப்பில் ஆரோக்கியம் ஏகொன் ,பெக்டன் டிக்கின்சன் ,தொற்று திஸ் ,ஆரோக்கியம் ஏகொன் பாலிஸீ ,